Pliant Therapeutics, Inc. (PLRX)
NMS · Healthcare · Biotechnology
$1.17
+3.54%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$72.4M
Shares Outstanding
61.9M
Exchange
NMS
Currency
USD
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (28.3M) | (23.6M) | (21.8M) | (23.9M) |
| Net Income | (26.3M) | (23.6M) | (20.0M) | (22.4M) |
| Diluted EPS | $-0.43 | $-0.38 | $-0.32 | $-0.36 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 9.7M | 1.6M | 0.00 | 0.00 |
| Operating Income | (127.2M) | (184.1M) | (228.4M) | (156.4M) |
| Net Income | (123.3M) | (161.3M) | (210.3M) | (149.3M) |
| Diluted EPS | $-2.94 | $-2.75 | $-3.47 | $-2.43 |